Abstract:Summary Background & Aims Butyrate (one of the short-chain fatty acids), a major byproduct of the fermentation of non-digestible carbohydrates (e.g. fiber), is supposed to have anti-obesity and anti-inflammatory properties. However, butyrate's potential and mechanism in preventing obesity and the efficient form of administration remain to be clarified. Methods Hence, we studied the effect of oral supplementation with 5% (w/w) sodium butyrate and 4% (w/w) β-glucan (fiber) in young male mice (C57BL/6J) with high-fat diet-induced obesity (HFD: 60 kcal% of fat + 1% of cholesterol). 6 weeks old mice were fed diets based on HFD or control (AIN) diet with/without supplements for 4 weeks. The unique, interdisciplinary approach combining several Raman-based techniques techniques (including Raman microscopy and fiber optic Raman spectroscopy) and next-generation sequencing was used to ex vivo analyze various depots of the adipose tissue (white, brown, perivascular) and gut microbiome, respectively. Results The findings demonstrate that sodium butyrate more effectively prevent the pathological increase in body weight caused by elevated saturated fatty acids influx linked to a HFD in comparison to β-glucan, thereby entirely inhibiting diet-induced obesity. Moreover, butyrate significantly affects the white adipose tissue (WAT) reducing the epididymal WAT mass in comparison to HFD without supplements, and decreasing lipid saturation in the epididymal WAT and thoracic aortic perivascular adipose tissue. Contrarily, β-glucan significantly changes the composition and diversity of the gut microbiome, reversing the effect of the HF diet, but shows no effect on the epididymal WAT mass and therefore the weight gain inhibition is not as effective as with sodium butyrate. Conclusions Here, oral supplementation with sodium butyrate and β-glucan (fiber) has been proven to have an anti-obesity effect through two different targets. Administration-dependent effects that butyrate imposes on the adipose tissue (oral administration) and microbiome (fiber-derived) make it a promising candidate for the personalized treatment of obesity.

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use

Protective role of butyrate in obesity and diabetes: New insights

Butyrate and obesity: Current research status and future prospect

The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

Gut microbial metabolites in obesity, NAFLD and T2DM

Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes

Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes

Direct oral and fiber-derived butyrate supplementation as an anti-obesity treatment via different targets

Clostridium butyricum Reduces Obesity in a Butyrate-Independent Way

Gut Microbial-Derived Short Chain Fatty Acids: Impact on Adipose Tissue Physiology

Butyrate-producing bacteria as probiotic supplement: beneficial effects on metabolism and modulation of behaviour in an obesity mouse model

Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms

Short chain fatty acids in human gut and metabolic health

Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit

Beyond Diet and Exercise: The Impact of Gut Microbiota on Control of Obesity

Butyrate as a potential therapeutic agent for neurodegenerative disorders

Importance of gut microbiota in obesity

Gut Microbiome Modulation Based on Probiotic Application for Anti-Obesity: A Review on Efficacy and Validation

Gut microbiota in obesity and metabolic disorders

Review of the effects of sodium butyrate on obesity, inflammatory bowel disease, pregnancy and colorectal cancer

Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?